Professional
Added to YB: 2026-01-16
Pitch date: 2025-12-31
JNJ [neutral]
Johnson & Johnson
+6.16%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
Market Cap
$526.6B
Pitch Price
$206.82
Price Target
N/A
Dividend
2.38%
EV/EBITDA
17.24
P/E
21.12
EV/Sales
6.01
Sector
Pharmaceuticals
Category
growth
Show full summary:
Mar Vista U.S. Quality Strategy Portfolio Holding: Johnson & Johnson
JNJ (holding update): Strong Q4 performance with robust pharma & medtech growth, upward guidance revisions. Management expects 5-7% revenue growth through 2030 (above consensus) despite Stelara generic headwinds. Consistent execution across segments drove outperformance vs broader market.
Read full article (1 min)